Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)

Abstract Objectives We evaluated the impact of age in a randomized phase II trial that compared three first-line drugs in elderly patients with advanced non-small cell lung cancer (NSCLC) and a poor performance status (PS). Materials and Methods Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. We performed subgroup analyses according to age. Results Between December 2004 and June 2007, 127 patients were enrolled. Analyses were performed between the two subgroups aged n  = 56) and ≥ 70 years (older, n  = 71). Patients mainly had adenocarcinoma (46% young vs. 51%: elderly), of which 62% vs. 75% had a PS of 2, respectively. Significantly more elderly patients were women and non-smokers, and there was a non-significant trend towards more PS-2 among the elderly. Progression-free survival (PFS) was 1.4 months (95% CI: 1.1–1.9) for younger compared to 2.3 months (95% CI: 2.1–2.9) for elderly patients. Overall survival (OS) was 2.0 months (95% CI: 1.5–2.4) and 3.7 months (95% CI: 2.4–4.8), respectively. Toxicity did not differ between younger and older patients. NSCLC was better controlled in elderly patients after three cycles of monotherapy compared to younger patients ( p  = 0.034). When adjusted for stratification criteria, age was the main prognostic factor for PFS. Adjusted HRs for PFS was 0.57 (95% CI: 0.38–0.85) for the elderly compared to patients aged p  = 0.004). Conclusions Older patients had a decreased risk of progression/death compared to younger patients. Single-agent chemotherapy can be considered for patients aged ≥ 70 years with a PS of 2.